Mixed Results For China’s First Home-Grown COVID Antiviral

Russia Trial Meets Endpoints

 
• By Dexter Jie Yan
  
azvudine trial results
Genuine Biotech needs to submit complete Phase III data for azvudine within three years of conditional approval • Source: Shutterstock

More from China

More from Focus On Asia